Home › Compare › CASBF vs NNN

CASBF vs NNN: Dividend Comparison 2026

CASBF yields 51.81% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CASBF wins by $4.4K in total portfolio value
10 years
CASBF
CASBF
● Live price
51.81%
Share price
$3.86
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.0K
Annual income
$7.71
Full CASBF calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — CASBF vs NNN

📍 CASBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCASBFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CASBF + NNN cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CASBF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CASBF
Annual income on $10K today (after 15% tax)
$4,404.15/yr
After 10yr DRIP, annual income (after tax)
$6.55/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, NNN beats the other by $2,235.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CASBF + NNN for your $10,000?

CASBF: 50%NNN: 50%
100% NNN50/50100% CASBF
Portfolio after 10yr
$27.8K
Annual income
$1,322.56/yr
Blended yield
4.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

CASBF
No analyst data
Altman Z
2.6
Piotroski
4/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CASBF buys
0
NNN buys
0
No recent congressional trades found for CASBF or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCASBFNNN
Forward yield51.81% ✓5.68%
Annual dividend / share$2.00$2.38 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%8.6% ✓
Portfolio after 10y$30.0K ✓$25.6K
Annual income after 10y$7.71$2,637.42 ✓
Total dividends collected$6.0K$13.7K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CASBF vs NNN ($10,000, DRIP)

YearCASBF PortfolioCASBF Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$13,291$2,590.67$10,737$617.02+$2.6K → CASBF
2$15,830$1,608.96$11,577$710.93+$4.3K → CASBF
3$17,834$895.50$12,538$822.59+$5.3K → CASBF
4$19,553$471.42$13,645$956.06+$5.9K → CASBF
5$21,164$241.53$14,925$1,116.51+$6.2K → CASBF
6$22,767$122.16$16,415$1,310.57+$6.4K → CASBF
7$24,422$61.41$18,158$1,546.77+$6.3K → CASBF
8$26,163$30.78$20,213$1,836.20+$6.0K → CASBF
9$28,010$15.41$22,649$2,193.37+$5.4K → CASBF
10$29,978$7.71$25,558$2,637.42+$4.4K → CASBF

CASBF vs NNN: Complete Analysis 2026

CASBF — Stock

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Full CASBF Calculator →

NNN — REIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this CASBF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CASBF vs SCHDCASBF vs JEPICASBF vs OCASBF vs KOCASBF vs MAINCASBF vs ADCCASBF vs EPRTCASBF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.